BACKGROUND The effects of mammalian target of rapamycin (mTOR) inhibition are limited
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …

Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …

5009 Background: Preclinical and phase 1 results suggest PI3K/mTOR pathway inhibition
may enhance androgen receptor inhibition. We report the results of a double-blind, placebo …

Background Despite frequent PTEN (phosphatase and tensin homologue) loss and
Akt/mammalian target of rapamycin (mTOR) signaling in prostate cancer, the disease is …

Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through
vascular endothelial growth factor (VEGF) have been shown to play important roles in …

BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …

5030 Background: Insulin-like growth factor receptor-1 (IGF-1R) signaling activates the
PI3K/AKT pathway and may lead to androgen receptor (AR) transactivation and progression …

Abstract Background Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway
activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib …

5025 Background: PI3K pathway activation is common in mCRPC. BKM120 (buparlisib) is
an oral, pan-class I PI3 kinase inhibitor. Preclinical data demonstrated a reciprocal feedback …